Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Invested Capital: 2012-2025

Historic Invested Capital for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to $64.7 million.

  • Enanta Pharmaceuticals' Invested Capital fell 49.76% to $64.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.7 million, marking a year-over-year decrease of 49.76%. This contributed to the annual value of $64.7 million for FY2025, which is 49.76% down from last year.
  • According to the latest figures from Q3 2025, Enanta Pharmaceuticals' Invested Capital is $64.7 million, which was down 18.37% from $79.3 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' Invested Capital's 5-year high stood at $436.0 million during Q1 2021, with a 5-year trough of $64.7 million in Q3 2025.
  • For the 3-year period, Enanta Pharmaceuticals' Invested Capital averaged around $155.4 million, with its median value being $148.9 million (2024).
  • Data for Enanta Pharmaceuticals' Invested Capital shows a maximum YoY tumbled of 49.76% (in 2025) over the last 5 years.
  • Enanta Pharmaceuticals' Invested Capital (Quarterly) stood at $384.4 million in 2021, then decreased by 21.74% to $300.8 million in 2022, then plummeted by 36.22% to $191.9 million in 2023, then plummeted by 41.73% to $111.8 million in 2024, then crashed by 49.76% to $64.7 million in 2025.
  • Its last three reported values are $64.7 million in Q3 2025, $79.3 million for Q2 2025, and $93.5 million during Q1 2025.